Article Text

Download PDFPDF
Antinuclear antibodies directed against proliferating cell nuclear antigen are not specifically associated with systemic lupus erythematosus
  1. P Vermeersch1,
  2. K Op De Beeck1,
  3. B R Lauwerys2,
  4. K Van den Bergh1,
  5. M Develter1,
  6. G Mariën1,
  7. F A Houssiau2,
  8. X Bossuyt1
  1. 1
    Department of Laboratory Medicine, Immunology, University Hospitals Leuven, Catholic University of Leuven, Belgium
  2. 2
    Department of Rheumatology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
  1. Correspondence to Dr X Bossuyt, Laboratory Medicine, Immunology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium; Xavier.bossuyt{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Proliferating cell nuclear antigen (PCNA) is an intranuclear protein that plays a role in DNA repair and replication. Anti-PCNA antibodies are considered a rare but highly specific marker for systemic lupus erythematosus (SLE).1 Anti-PCNA antibodies are reported to occur in approximately 2–6% of patients with SLE.2 3 Given the rare occurrence, however, little is known about the clinical relevance of a positive anti-PCNA test.

To examine whether anti-PCNA antibodies are specifically associated with SLE, we retrospectively identified all patients with anti-PCNA antibodies at the University Hospitals Leuven over a 10-year period (January 1998–December 2007). Patient sera submitted for antinuclear antibody testing were tested by conventional immunofluorescence using Hep2 …

View Full Text


  • Competing interests None.

  • Ethics approval Ethics approval was granted by the Institutional Review Board.